

CARDIAC CHANGES DUE TO CHEMOTHERAPY IN CHILDHOOD LEUKEMIA

THESIS

Submitted for partial fulfilment of

M.D. Pediatrics




By

Nagham M. Sami Abdel Hafez El-Biblawy

M.B., B.Ch. – Ain Shams University 1987

M.Sc. Ped. – Ain Shams University 1991



Supervisors

Prof. Ahmed Samy Khalifa

Professor of Pediatrics

Ain Shams University

63061 رشتة

Prof. Khairy Abdel Dayem

Professor of Cardiology

Ain Shams University

Prof. Wagih Naguib Ibrahim

Professor of Clinical Pathology

Ain Shams University

Assistant Supervisor

Dr. Maiy Hamdy El-Sayed

Lecturer of Cardiology

Ain Shams University

Handwritten signature

Handwritten signature

Ain Shams University

1995

بسم الله الرحمن الرحيم

﴿سبحانك لا علم لنا إلا ما علمتنا إنك أنت العليم الحكيم﴾

صدق الله العظيم

| الآية : ٢٢ |



ACKNOWLEDGEMENT

Thanks to GOD firstly and Lastly.

It is a great honour to express my deep gratitude and appreciation to Prof. Dr. Ahmed Samy Khalifa, Professor of Pediatrics, Ain Shams University, for his cooperation and continuous guidance. He has sacrificed a lot of his busy time to teach me and revise every step of this thesis.

I am indebted to Prof. Dr. Khairy Abdel Dayem, Professor of Cardiology, Ain Shams University, for his unlimited support throughout the work,

I owe a debt of gratitude to Prof. Dr. Wagih Naguib Ibrahim, Professor of Clinical Pathology, Ain Shams University, for his continuous help and continuous follow up.

I also wish to express my sincere appreciation to Dr. Maiy Hamdy El-Sayed, Lecturer of Cardiology, Ain Shams University, for her indispensable help.

Special gratitude and deep appreciation are due to Dr. Nashwa El-Badawy, Lecturer of Clinical Pathology Ain Shams University, for her meticulous work and close supervision.

I also thank Dr. Hossam El Ghetany, Lecturer of Cardiology, Ain Shams University, for his help.

I would also like to thank all my patients and their families for their cooperation.

Finally, I acknowledge my family, colleagues and all those who helped me in this work.

To ...

My family.

My husband.



CONTENTS

	Page
Introduction and Aim of Work	1
Review of Literature	2
Childhood Acute leukemia	2
Cardiac Manifestations in Acute Leukemia	32
Cardiac Toxicity of Cancer Therapy	42
Enzymes in Myocardial Cells	66
Echocardiography	77
Subjects and Methods	94
Results	107
Discussion	176
Summary and Conclusion	194
Recommendations	201
References	202
Arabic Summary	

LIST OF TABLES

	Page
Table (1): French-American-British (FAB) Classification of Acute Lymphoblastic Leukemia.	10
Table (2): Reaction of acute leukemic cells to cytochemical stains.	15
Table (3): Translocations common in childhood ALL.	18
Table (4): Hematopoietic growth factors and some of their characteristics.	31
Table (5): Features of the four anthracyclines in current clinical use.	58-59
Table (6): Amplitude measurements in children.	97
Table (7): Clinical, hematological and cardiac evaluation data of the control group.	108-110
Table (8): Clinical, hematological and cardiac evaluation data of newly diagnosed patients of ALL before chemotherapy.	113-115
Table (9): Comparative study between newly diagnosed patients of ALL before chemotherapy and control group.	116
Table (10): Clinical, hematological and cardiac evaluation data in patients of ALL after induction of remission.	120-122
Table (11): Comparative study between patients of ALL after induction of remission and control group.	123
Table (12): Clinical, hematological and cardiac evaluation data in patients of ALL after 6 weeks of maintenance therapy.	127-129
Table (13): Comparative study between patients of ALL after 6 weeks of maintenance therapy and control group.	130

	Page
Table (14): Clinical, hematological and cardiac evaluation data in patients of ALL after 6 months of recycling chemotherapy from the end of maintenance treatment.	134–136
Table (15): Comparative study between patients of ALL after 6 months of recycling chemotherapy from the end of maintenance treatment and control group.	137
Table (16): Clinical, hematological and cardiac evaluation data in patients of ALL who received about 25% of the maximum cumulative dose of doxorubicin (550 mg/m ²).	140–143
Table (17): Comparative study between patients of ALL who received about 25% of the maximum cumulative dose of doxorubicin and control group.	144
Table (18): Clinical, hematological and cardiac evaluation data in patients of ALL who received about 50% of the maximum cumulative dose of doxorubicin (550 mg/m ²).	147–150
Table (19): Comparative study between patients of ALL who received about 50% of the maximum cumulative dose of doxorubicin and control group.	151
Table (20): Clinical, hematological and cardiac evaluation data in patients of ALL who received about 100% of the maximum cumulative dose of doxorubicin (550 mg/m ²).	154–157
Table (21): Comparative study between patients of ALL who received about 100% of the maximum cumulative dose of doxorubicin and control group.	158
Table (22): Results of ANOVA in patients who received 25%, 50% and 100% of the maximum cumulative dose of doxorubicin.	162
Table (23): Results of ANOVA in patients of ALL before chemotherapy and at different stages of treatment.	164

LIST OF FIGURES

	Page
Fig. (1): Structures of the four anthracyclines in current clinical use.	43
Fig (2): Diagrammatic presentation of M-mode echocardiogram as the transducer is directed from the apex to the base.	78
Fig (3): Representation of an M-mode echocardiographic recording as the ultrasonic beam is swept from the apex to the base of the heart.	79
Fig (4a): Different approaches of two-dimensional echocardiographic examination.	81
Fig (4b): Echocardiographic image of parasternal long-axis view.	82
Fig (4c): Echocardiographic image of parasternal short-axis view.	83
Fig (4d): Echocardiographic image of the family of two-dimensional apical views.	84
Fig (4e): Echocardiographic image of subcostal view.	85
Fig (4f): Echocardiographic image of suprasternal view.	86
Fig. (5): Cardiomegaly in a newly diagnosed patient of ALL.	117
Fig. (6): Pericardial effusion shown by two-dimensional parasternal long axis view in a newly diagnosed patient of ALL.	117
Fig. (7): Pericardial effusion shown by two-dimensional parasternal long axis view in a patient of ALL after induction of remission.	124

	Page
Fig. (8): Pericardial effusion shown by four-chamber apical view in a patient of ALL after 6 weeks of maintenance therapy.	131
Fig. (9): Cardiomegaly in a patient of ALL with doxorubicin induced cardiomyopathy.	159
Fig. (10): Four-chamber apical view showing doxorubicin induced cardiomyopathy.	159
Fig. (11): Mild to moderate mitral regurgitation shown by Doppler echocardiography in a patient with doxorubicin induced cardiomyopathy.	160
Fig. (12): C/T ratio in different studied groups.	165
Fig. (13): HR in different studied groups.	166
Fig. (14): AST level in different studied groups.	167
Fig. (15): LDH level in different studied groups.	168
Fig. (16): Total CK level in different studied groups.	169
Fig. (17): CK-MB level in different studied groups.	170
Fig. (18): EDD in different studied groups.	171
Fig. (19): ESD in different studied groups.	172
Fig. (20): SV in different studied groups.	173
Fig. (21): FS in different studied groups.	174
Fig. (22): EF in different studied groups.	175

LIST OF ABBREVIATIONS

A velocity	Late peak filling velocity
AAW	Anterior aortic wall
ALL	Acute lymphoblastic leukemia
AML	Acute myeloblastic leukemia
AMML	Acute myelomonocytic leukemia
AMOL	Acute monocytic leukemia
AMVL	Anterior mitral valve leaflet
ANLL	Acute non lymphoblastic leukemia
ANOVA	Analysis of variance
Ao root D	Aortic root dimension
AOV	Aortic valve
APS	Atriopulmonary sulcus
ARVW	Anterior right ventricular wall
AST	Aspartate aminotransferase
ATP	Adenosine triphosphate
ATVL	Anterior tricuspid valve leaflet
BFU	Burst forming unit
BMT	Bone marrow transplantation
C/T ratio	Cardiothoracic ratio
CALLA	Common acute lymphoblastic leukemia antigen
CFU	Colony forming unit
Ch	Chordae tendineae
cIg ⁺ a	Cytoplasmic immunoglobulin positive
CK	Creatine kinase
CK-MB	Creatine kinase MB
CNS	Central nervous system
Cond	Conduction

CSF	Colony stimulating factor
CW	Chest wall
DNA	Deoxyribonucleic acid
E velocity	Early peak filling velocity
ECG	Electrocardiogram
EDD	End diastolic dimension
EDV	End diastolic volume
EF	Ejection fraction
ESD	End systolic dimension
ESV	End systolic volume
FAB	French American British
FAB-E	French American British Egyptian
FS	Fraction shortening
GEMM	Granulocytes, erythroid cells, macrophages, megakaryocytes
GM-CSF	Granulocyte-macrophage colony stimulating factor
H ₂ O ₂	Hydrogen peroxide
Hb	Hemoglobin
HR	Heart rate
IFN	Interferon
IL	Interleukin
IVS	Interventricular septum
IVSd	Interventricular septal thickness
LA	Left atrium
LADs	Left atrial dimension
LAW	Left atrial wall
LDH	Lactate dehydrogenase
LV	Left ventricle
LVEF	Left ventricle ejection fraction
LVOT	Left ventricular outflow tract
LVPWd	Left ventricular posterior wall thickness

McAbs	Monoclonal antibodies
PA	Pulmonary artery
PAS	Periodic acid Schiff
PAW	Posterior aortic wall
PE	Pericardial effusion
Perc	Percentile
Ph+	Philadelphia chromosome positive
Plts	Platelets
PLVW	Posterior left ventricular wall
PMVL	Posterior mitral valve leaflet
PPM	Posterior papillary muscle
PV	Pulmonary valve
RA	Right atrium
RNA	Ribonucleic acid
RV	Right ventricle
RVDd	Right ventricular dimension
RVOT	Right ventricular outflow tract
SA	Surface area
sIg ⁺ a	Surface immunoglobulin positive
SV	Stroke volume
TdT	Terminal deoxynucleotidyl transferase
TLC	Total leukocytic count
TV	Tricuspid valve
WBC	White blood cell

Introduction and Aim of Work

INTRODUCTION AND AIM OF WORK

With advances in the effective treatment of childhood leukemias using combination chemotherapy, toxicities have emerged as major causes of morbidity and mortality during the therapy of these hematologic malignancies (*Balis, 1988*).

Anthracyclines are effective antineoplastic agents for treatment of many pediatric solid tumors and hematologic malignancies (*Marchandise et al., 1989*). However, their use is limited by toxic cardiomyopathy resulting in irreversible myocyte damage with both acute and chronic effects (*Steinherz et al., 1991*). The incidence of doxorubicin cardiotoxicity increases at cumulative doses greater than 550 mg/m² (*Steinherz et al., 1992*).

Aim of the Work

The aim of this study is to identify anthracycline cardiotoxicity in different groups of patients who received variable percentages of the maximum cumulative dose of the drug to detect changes that might necessitate discontinuation of anthracycline therapy.
